ORGO Valuation

Organogenesis Holdings Inc

Add to Watchlist

Advanced Chart

4.470

-0.11(-2.402%)1D

Overview
Forecast
Valuation
Earnings

ORGO Relative Valuation

ORGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ORGO is overvalued; if below, it's undervalued.

Historical Valuation

Organogenesis Holdings Inc (ORGO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.02 is considered Fairly compared with the five-year average of 37.55. The fair price of Organogenesis Holdings Inc (ORGO) is between 3.06 to 12.65 according to relative valuation methord.

Relative Value

Fair Zone

3.06-12.65

Current Price：4.58

Fair

16.36

Trailing

Forward

11.77

EV/EBITDA

Organogenesis Holdings Inc. (ORGO) has a current EV/EBITDA of 11.77. The 5-year average EV/EBITDA is 14.46. The thresholds are as follows: Strongly Undervalued below 0.62, Undervalued between 0.62 and 7.54, Fairly Valued between 21.38 and 7.54, Overvalued between 21.38 and 28.30, and Strongly Overvalued above 28.30. The current Forward EV/EBITDA of 11.77 falls within the Historic Trend Line -Fairly Valued range.

13.11

EV/EBIT

Organogenesis Holdings Inc. (ORGO) has a current EV/EBIT of 13.11. The 5-year average EV/EBIT is 32.11. The thresholds are as follows: Strongly Undervalued below -86.47, Undervalued between -86.47 and -27.18, Fairly Valued between 91.40 and -27.18, Overvalued between 91.40 and 150.68, and Strongly Overvalued above 150.68. The current Forward EV/EBIT of 13.11 falls within the Historic Trend Line -Fairly Valued range.

0.99

Organogenesis Holdings Inc. (ORGO) has a current PS of 0.99. The 5-year average PS is 1.68. The thresholds are as follows: Strongly Undervalued below -0.98, Undervalued between -0.98 and 0.35, Fairly Valued between 3.01 and 0.35, Overvalued between 3.01 and 4.34, and Strongly Overvalued above 4.34. The current Forward PS of 0.99 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Organogenesis Holdings Inc. (ORGO) has a current P/OCF of 0.00. The 5-year average P/OCF is 16.68. The thresholds are as follows: Strongly Undervalued below -24.42, Undervalued between -24.42 and -3.87, Fairly Valued between 37.23 and -3.87, Overvalued between 37.23 and 57.77, and Strongly Overvalued above 57.77. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Organogenesis Holdings Inc. (ORGO) has a current P/FCF of 0.00. The 5-year average P/FCF is -6.78. The thresholds are as follows: Strongly Undervalued below -374.01, Undervalued between -374.01 and -190.39, Fairly Valued between 176.84 and -190.39, Overvalued between 176.84 and 360.45, and Strongly Overvalued above 360.45. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Organogenesis Holdings Inc (ORGO) has a current Price-to-Book (P/B) ratio of 2.44. Compared to its 3-year average P/B ratio of 1.58 , the current P/B ratio is approximately 54.27% higher. Relative to its 5-year average P/B ratio of 4.36, the current P/B ratio is about -44.06% higher. Organogenesis Holdings Inc (ORGO) has a Forward Free Cash Flow (FCF) yield of approximately -7.98%. Compared to its 3-year average FCF yield of -0.54%, the current FCF yield is approximately 1370.11% lower. Relative to its 5-year average FCF yield of -0.33% , the current FCF yield is about 2305.81% lower.

2.49

P/B

Median3y

1.58

Median5y

4.36

-8.16

FCF Yield

Median3y

-0.54

Median5y

-0.33

Competitors Valuation Multiple

The average P/S ratio for ORGO's competitors is 1.74, providing a benchmark for relative valuation. Organogenesis Holdings Inc Corp (ORGO) exhibits a P/S ratio of 0.99, which is -42.70% above the industry average. Given its robust revenue growth of -22.44%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ORGO.O

Organogenesis Holdings Inc

Castle Biosciences Inc

Performance Decomposition

Market capitalization of ORGO increased by 55.21% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -17.89 to -36.96.

The secondary factor is the Revenue Growth, contributed -22.44%to the performance.

Overall, the performance of ORGO in the past 1 year is driven by P/E Change. Which is more unsustainable.

-22.44%

130.23M → 101.01M

Revenue Growth

-28.95%

-13.09 → -9.30

Margin Expansion

106.60%

-17.89 → -36.96

P/E Change

55.21%